HS
APGE

HighVista Strategies’s Apogee Therapeutics APGE Stock Holding History

HighVista Strategies’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-35,761
Closed -$3.01M – 149
2026
Q1 		$3.01M Sell
35,761
-53,468
-60% -$3.88M 0.83% 35
2025
Q4 		$6.74M Sell
89,229
-17,878
-17% -$1.13M 1.73% 13
2025
Q3 		$4.26M Buy
107,107
+62,055
+138% +$2.37M 1.04% 24
2025
Q2 		$1.96M Buy
45,052
+1,862
+4% +$70.8K 0.72% 46
2025
Q1 		$1.61M Hold
43,190
– – 0.62% 59
2024
Q4 		$1.96M Sell
43,190
-18,598
-30% -$948K 0.73% 45
2024
Q3 		$3.63M Sell
61,788
-17,154
-22% -$822K 1.25% 19
2024
Q2 		$3.11M Sell
78,942
-40,461
-34% -$1.96M 1.13% 18
2024
Q1 		$7.93M Buy
+119,403
New +$5.21M 2.83% 2

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

HighVista Strategies's APGE Position: Q2 2026 in Review

HighVista Strategies sold out of Apogee Therapeutics (APGE) in Q2 2026, closing a stake of 35,761 shares — an estimated $3.01M sold.

HighVista Strategies first reported a position in APGE in Q1 2024 and held it in 9 quarters. The position peaked at $7.93M in Q1 2024. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • HighVista Strategies reported no remaining Apogee Therapeutics position as of Q2 2026 after selling out during the quarter.
  • HighVista Strategies sold 35,761 Apogee Therapeutics shares in Q2 2026, an estimated $3.01M.
  • HighVista Strategies first reported a position in Apogee Therapeutics in Q1 2024 and held it in 9 quarters.
  • HighVista Strategies's Apogee Therapeutics position peaked at $7.93M in Q1 2024.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.